Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

Summary

This research study will explore the safety and efficacy of the drug, pirfenidone, in patients with a diagnosis of Hermansky-Pudlak Syndrome (HPS) who have an associated interstitial lung disease (ILD) over a planned period of 56 weeks.

Timeline

Start

2019-12-01

Primary completion

2022-12-31

Completion

2022-12-31

Drugs

Indications